AMC stock stabilizes above 200-day SMA as Macquarie lifts target
AMC Entertainment Holdings Inc shares rose 0.53% to $1.91 as Macquarie raised its price target to $2.00 and lifted its 2026 EBITDA estimate to $629 million. The firm cited stronger-than-expected theater demand and a 2026 industry box office forecast of $9.8 billion. AMC continues to trade below its 20-day SMA but holds above the 50-day and 200-day SMAs, with an RSI of 48.28 indicating neutral momentum.

*this image is generated using AI for illustrative purposes only.
AMC Entertainment Holdings Inc (NYSE: AMC) shares rose 0.53% to $1.91 on Friday as traders leaned into a more constructive box-office outlook and a fresh analyst target hike. The stock is attempting to stabilize above key long-term moving averages after recent volatility, though it remains down 36% over the past 12 months. Macquarie maintained a Neutral rating but raised its price target to $2.00 from $1.50, citing improved industry fundamentals and a better box office setup.
Analyst Projections and Box Office Outlook
Macquarie raised its 2026 adjusted EBITDA estimate to $629 million from $600 million and narrowed its projected full-year adjusted loss to 24 cents per share from a prior loss estimate of 28 cents. The upgrade follows a second quarter where U.S. box office admissions revenue reached $2.97 billion, up 11% year-over-year. This marked the strongest second-quarter domestic box office in six years. Macquarie raised its 2026 industry box office forecast to $9.8 billion, up 13% year-over-year, noting that higher attendance directly supports ticket sales, concessions, and operating leverage. The firm flagged rising costs and a slower recovery as key risks.
Capital Structure and Debt Strategy
AMC is trading with dilution sensitivity in the background after a $200 million registered direct offering that issued 95,250,000 shares. The company stated it planned to use net proceeds primarily to redeem $125,471,000 of 6.125% Senior Subordinated Notes due 2027. AMC indicated it does not anticipate material debt principal repayments until calendar year 2029.
Technical Levels and Momentum
From a technical perspective, AMC is trading 10.1% below its 20-day SMA ($2.14), even as it holds above the 50-day SMA ($1.82) and the 200-day SMA ($1.84). The Relative Strength Index (RSI) is at 48.28, indicating a neutral momentum reading. This technical profile suggests a bounce inside a bigger range, with the 50-day SMA still below the 200-day SMA despite the 20-day SMA sitting above the 50-day SMA.
| Metric | Value |
|---|---|
| 20-day SMA | $2.14 |
| 50-day SMA | $1.82 |
| 200-day SMA | $1.84 |
| 12-month Change | -36% |
Key resistance is identified at $2.00, a round-number area near the 20-day EMA where rebounds can stall. Macquarie noted that while faster box office improvement could support further upside, rising costs and a slower recovery remain downside risks.
How will AMC balance the need for further capital raising against shareholder dilution risks if the box office recovery slows?
What specific cost-cutting measures is AMC implementing to mitigate the rising operational expenses flagged by Macquarie?
Could the recent debt redemption strategy delay AMC's ability to invest in new theater technologies or expansion?



























